## Helene Peyriere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9448641/publications.pdf

Version: 2024-02-01

331259 360668 1,317 45 21 35 h-index citations g-index papers 58 58 58 1417 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Chemsex practice in France: An update in Addictovigilance data. Fundamental and Clinical Pharmacology, 2022, 36, 397-404.	1.0	30
2	A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007–2019). Drug Safety, 2022, 45, 37-44.	1.4	5
3	Opioid misuse in community pharmacy patients with chronic nonâ€eancer pain. British Journal of Clinical Pharmacology, 2022, 88, 2306-2314.	1.1	2
4	Abuse and misuse of secondâ€generation antipsychotics: An analysis using VigiBase, the World Health Organisation pharmacovigilance database. British Journal of Clinical Pharmacology, 2022, 88, 4646-4653.	1.1	5
5	Tenâ€year trend of opioid and nonopioid analgesic use in the French adult population. British Journal of Clinical Pharmacology, 2021, 87, 555-564.	1.1	19
6	Characterization of benzodiazepine misuse and comorbidities in patients with alcohol use disorder. Fundamental and Clinical Pharmacology, 2021, 35, 1133-1140.	1.0	2
7	Bacterial infections in people who inject psychoactive substances: An observational study in a French university hospital. Therapie, 2021, 76, 539-547.	0.6	3
8	Risk assessment of using off″abel morphine sulfate in a populationâ€based retrospective cohort of opioidâ€dependent patients. British Journal of Clinical Pharmacology, 2020, 86, 2338-2348.	1.1	6
9	Medication errors involving opioid maintenance therapy. Therapie, 2020, 75, 295-297.	0.6	2
10	Complications Related to Sexualized Drug Use: What Can We Learn From Literature?. Frontiers in Neuroscience, 2020, 14, 548704.	1.4	34
11	Clomiphene misuse and risk of severe cardiovascular events. European Journal of Clinical Pharmacology, 2020, 76, 901-902.	0.8	2
12	Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie, 2020, 75, 343-354.	0.6	54
13	Use of new psychoactive substances to mimic prescription drugs: The trend in France. NeuroToxicology, 2020, 79, 20-24.	1.4	21
14	Implementing screening, brief intervention and referral to treatment in a French cohort of people living with HIV: a pilot study. HIV Medicine, 2019, 20, 286-290.	1.0	2
15	High Prevalence of Misuse of Prescribed Opioid Analgesics in Patients with Chronic Non-Cancer Pain. Journal of Psychoactive Drugs, 2019, 51, 371-376.	1.0	7
16	Distinct Profiles of Consumers of Psychoactive Substances in People Attending French Sexual Transmitted Infections Centers. AIDS and Behavior, 2019, 23, 3375-3383.	1.4	1
17	Psychoactive substances, alcohol and tobacco consumption in HIV-infected outpatients. Aids, 2018, 32, 1165-1171.	1.0	11
18	Evidence of slowâ€release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area. Fundamental and Clinical Pharmacology, 2016, 30, 466-475.	1.0	22

#	Article	IF	Citations
19	Medical complications of psychoactive substances with abuse risks: Detection and assessment by the network of French addictovigilance centres. Therapie, 2016, 71, 563-573.	0.6	9
20	Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria. PLoS ONE, 2015, 10, e0142491.	1.1	8
21	Prevalence of levamisole and aminorex in patients tested positive for cocaine in a French University Hospital. Clinical Toxicology, 2015, 53, 604-608.	0.8	18
22	Identification and collection of abuse cases in the emergency department through a hospital database. Clinical Toxicology, 2015, 53, 138-139.	0.8	4
23	Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction. European Journal of Clinical Pharmacology, 2015, 71, 1539-1540.	0.8	8
24	Levamisole-Adulterated Cocaine: What about in European Countries?. Journal of Psychoactive Drugs, 2014, 46, 389-392.	1.0	34
25	Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clinical Toxicology, 2013, 51, 899-903.	0.8	43
26	Necrosis of the Intranasal Structures and Soft Palate as a Result of Heroin Snorting: A Case Series. Substance Abuse, 2013, 34, 409-414.	1.1	24
27	Slow-Release Oral Morphine Sulfate Abuse: Results of the Postmarketing Surveillance Systems for Psychoactive Prescription Drug Abuse in France. European Addiction Research, 2013, 19, 235-244.	1.3	27
28	Acute Hepatitis and Renal Failure Related to Intranasal Buprenorphine Misuse. Annals of Pharmacotherapy, 2013, 47, 1721-1726.	0.9	6
29	Viral and bacterial risks associated with mephedrone abuse in HIV-infected men who have sex with men. Aids, 2013, 27, 2971-2972.	1.0	9
30	Antihypertensive Drugs in Patients Treated with Antiretroviral. Annals of Pharmacotherapy, 2012, 46, 703-709.	0.9	28
31	Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica, 2010, 40, 701-706.	0.5	22
32	Hepatitis After Intravenous Injection of Sublingual Buprenorphine in Acute Hepatitis C Carriers: Report of Two Cases of Disappearance of Viral Replication After Acute Hepatitis. Annals of Pharmacotherapy, 2009, 43, 973-977.	0.9	30
33	Antipsychoticsâ€induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiology and Drug Safety, 2009, 18, 948-955.	0.9	81
34	Comparison of carbamazepine and oxcarbazepine effects on aminothiol levels. European Journal of Clinical Pharmacology, 2008, 64, 83-87.	0.8	3
35	Simultaneous Quantification of Voriconazole and Its N-Oxide Metabolite in Human Plasma by an Easy and Rapid Isocratic LC Method with UV Detection. Chromatographia, 2008, 67, 275-280.	0.7	9
36	Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database. Annals of Pharmacotherapy, 2007, 41, 755-763.	0.9	91

3

#	Article	IF	Citations
37	Inherited long QT syndrome revealed by antifungals drug?drug interaction. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 321-324.	0.7	29
38	Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. British Journal of Dermatology, 2006, 155, 422-428.	1.4	275
39	Neurotoxicity Related to Valganciclovir in a Child With Impaired Renal Function: Usefulness of Therapeutic Drug Monitoring. Annals of Pharmacotherapy, 2006, 40, 143-146.	0.9	23
40	Liquid chromatography–electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 828, 80-90.	1.2	137
41	Optimal Management of Methotrexate Intoxication in a Child with Osteosarcoma. Annals of Pharmacotherapy, 2004, 38, 422-427.	0.9	26
42	Reasons for Early Abacavir Discontinuation in HIV-Infected Patients. Annals of Pharmacotherapy, 2003, 37, 1392-1397.	0.9	38
43	Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Medical and Pediatric Oncology, 2001, 36, 662-664.	1.0	26
44	Application of a standardized coextractive cleanup procedure to routine high-performance liquid chromatography assays of teicoplanin and ganciclovir in plasma. Biomedical Applications, 1998, 705, 79-85.	1.7	28
45	Tenâ€year trends in hospitalizations related to cocaine abuse in France. Fundamental and Clinical Pharmacology, 0, , .	1.0	5